Brief: Hoth Therapeutics Delivers 100% Clinical Response With ~50% Reduction In Disease Severity In Open-Label PK Cohort Of EGFR-Treated Cancer Patients
22/01/2026 14:21
Jan 22 (Reuters) - Hoth Therapeutics Inc HOTH.O: HOTH THERAPEUTICS DELIVERS 100% CLINICAL RESPONSE WITH ~50% REDUCTION IN DISEASE SEVERITY IN OPEN-LABEL PK COHORT OF EGFR-TREATED CANCER PATIENTS HOTH THERAPEUTICS INC - HT-001 WELL TOLERATED WITH NO UNEXPECTED SAFETY SIGNALS HOTH THERAPEUTICS INC - ADDITIONAL ENDPOINTS SHOW ~34% IMPROVEMENT IN ONCOLOGY TOXICITY Source text: ID:nPn65gKMBa Further company coverage: HOTH.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rocket One
See all newsBrief: Rocket One Signs AI Chip Development Agreement Targeting Ultra-Low-Power Magnetic Computing
Brief: Rocket One Signs Agreement To Advance Nanomagnetic Ai Chip Technology And Device Prototyping
Brief: Rocket One Signs Patent License Agreement With U.S. Air Force For Technology Designed To Capture And Neutralize Hostile Drones
Brief: Rocket One To Buy 100% Ownership Of Tracer Drone Technologies
Brief: Rocket One And Nasa Reach Agreement To Advance Space Ai Technology